Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions | ADA
Tirzepatide: a new low for bodyweight and blood glucose - The Lancet Diabetes & Endocrinology
Spotlight on tirzepatide – EASD e-Learning
Type 2 Diabetes Drug Tirzepatide (Mounjaro) Aids Weight Loss in People With Obesity: Study | Everyday Health
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet
New Drug Tirzepatide Shows Extraordinary Results For Obesity and Type 2 Diabetes
Tirzepatide's Unique Mechanism of Action - GIP/GLP-1 Dual Agonist - YouTube
Adults with type 2 diabetes reach HbA1c target faster with tirzepatide than semaglutide
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial - The
Tirzepatide for diabetes: on track to SURPASS current therapy | Nature Medicine
Diabetes Distilled: The twincretin tirzepatide – a promising treatment for NAFLD - DiabetesontheNet
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
European Association for the Study of Diabetes - Free to read in Diabetologia: Management of type 2 #diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis https://link.springer.com/article/10.1007/s00125 ...
FDA Approves Drug Tirzepatide for Type 2 Diabetes
Tirzepatide (Mounjaro): A Q&A With the ADA's Dr. Robert Gabbay | Everyday Health
Tirzepatide achieves blood sugar control and weight-loss goals faster than existing diabetes drugs
SURPASS-5: Tirzepatide lowers HbA1c in adults with type 2 diabetes on insulin glargine
Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA
PDF) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes - Furihata - 2022 - Diabetes, Obesity and Metabolism - Wiley Online Library
Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist - ScienceDirect
